Myomo, Inc. (MYO)
AMEXHealth CareMedical - DevicesSnapshot 2026-11-04
$1.30+1.56%
Close 2026-11-04 · 1-day change
AMEXHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · MYO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -71.7% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 15.7% |
Growth built into the price is above our model estimate.
The price assumes 87.4 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 29 industry peers
MYO — director transition
Dated 2026-05-13
Director — Joseph M. Manko Jr.: Appointment of Joseph M. Manko Jr. to the Board of Directors.
Why it matters: Recurring sources made up 53% of Q2 revenue, up from 49% in Q1. A drop would reverse that progress.
Worry ifRecurring patient sources make up less than 50% of quarterly revenue.
Less concerning ifRecurring patient sources stay at or above 53% of revenue in the next reported quarter.
Why it matters: Management expects cash burn below $2 million in the second half of 2026. Higher use would challenge that goal.
Worry ifCash used in operations is above $2 million in Q3, or second-half cash use exceeds $2 million.
Less concerning ifQ3 cash used in operations is at or below $2 million, and second-half cash use stays below $2 million.
Why it matters: The planned trial has enrolled 25 of 50 subjects. Results may help support higher Medicare Advantage approval rates.
Supportive ifMyomo reports that the University of Utah trial enrolled all 50 planned subjects. It also shares results showing the main study goal was met.
Worry ifEnrollment remains below 50 at the next update, or results show the main study goal was not met.
Why it matters: Orders rose 23% year over year to 255 in Q2. More orders can support later revenue growth.
Supportive ifQ3 orders exceed 255 and are higher than Q3 2025 orders.
Worry ifQ3 orders are 255 or fewer, or fall below Q3 2025 orders.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$366 on $10,000 · ±3.7% | How much price usually moves either way. |
| Bad day | $894 loss on $10,000 · 8.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,156 loss on $10,000 · 41.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.